CCM
MRNA icon

CAAS Capital Management’s Moderna MRNA Stock Holding History

CAAS Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-25,700
Closed -$1.72M – 490
2024
Q3 		$1.72M Buy
25,700
+12,200
+90% +$1.12M 0.2% 111
2024
Q2 		$1.6M Sell
13,500
-21,200
-61% -$2.68M 0.52% 54
2024
Q1 		$3.7M Buy
+34,700
New +$3.5M 0.27% 99
2023
Q2 		– Sell
-21,100
Closed -$3.24M – 784
2023
Q1 		$3.24M Buy
+21,100
New +$3.48M 0.17% 137
2022
Q4 		– Sell
-32,900
Closed -$3.89M – 901
2022
Q3 		$3.89M Sell
32,900
-75,900
-70% -$11.5M 0.19% 168
2022
Q2 		$15.5M Buy
108,800
+104,800
+2,620% +$15M 0.78% 20
2022
Q1 		$689K Sell
4,000
-11,000
-73% -$1.85M 0.03% 355
2021
Q4 		$3.81M Hold
15,000
– – 0.09% 220
2021
Q3 		$5.77M Sell
15,000
-27,500
-65% -$10.1M 0.12% 177
2021
Q2 		$9.99M Hold
42,500
– – 0.17% 148
2021
Q1 		$5.57M Sell
42,500
-218,000
-84% -$31.6M 0.06% 330
2020
Q4 		$27.2M Buy
+260,500
New +$26.4M 0.26% 85

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

CAAS Capital Management's MRNA Position: Q4 2024 in Review

CAAS Capital Management sold out of Moderna (MRNA) in Q4 2024, closing a stake of 11,812 shares — an estimated $789K sold.

CAAS Capital Management first reported a position in MRNA in Q1 2021 and held it in 9 quarters. The position peaked at $3.72M in Q1 2021. 745 funds tracked by Wall St. Rank hold MRNA as of Q4 2024.

  • CAAS Capital Management reported no remaining Moderna position as of Q4 2024 after selling out during the quarter.
  • CAAS Capital Management sold 11,812 Moderna shares in Q4 2024, an estimated $789K.
  • CAAS Capital Management first reported a position in Moderna in Q1 2021 and held it in 9 quarters.
  • CAAS Capital Management's Moderna position peaked at $3.72M in Q1 2021.
  • 745 funds tracked by Wall St. Rank held Moderna as of Q4 2024.

Based on CAAS Capital Management's 13F filing for Q4 2024, filed 24 Jan 2025.